| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2026 | $32.00 | Buy | Canaccord Genuity |
| 4/24/2026 | $28.00 | Overweight | Barclays |
| 1/12/2026 | $43.00 | Buy | Guggenheim |
| 1/9/2026 | $33.00 | Equal Weight | Wells Fargo |
| 10/21/2025 | $74.00 | Neutral → Buy | Citigroup |
| 5/29/2025 | $44.00 | Neutral → Overweight | Piper Sandler |
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Canaccord Genuity initiated coverage of Claritev with a rating of Buy and set a new price target of $32.00
Barclays initiated coverage of Claritev with a rating of Overweight and set a new price target of $28.00
Guggenheim initiated coverage of Claritev with a rating of Buy and set a new price target of $43.00
Wells Fargo initiated coverage of Claritev with a rating of Equal Weight and set a new price target of $33.00
Citigroup upgraded Claritev from Neutral to Buy and set a new price target of $74.00
Piper Sandler upgraded Claritev from Neutral to Overweight and set a new price target of $44.00
8-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
DEFA14A - Claritev Corp (0001793229) (Filer)
DEF 14A - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
8-K - Claritev Corp (0001793229) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
4 - Claritev Corp (0001793229) (Issuer)
Fastest customizable press release news feed in the world
New Primary Network Solution Helps Balance Regional Access, National Reach, and Cost Discipline As healthcare costs accelerate and employers demand more control over network strategy, Claritev Corporation (NYSE:CTEV), a healthcare technology, data and insights company, today announced the launch of PHCS Novera, a primary network solution designed to help deliver flexible, competitive options. With nearly two-thirds of covered workers enrolled in self-funded insurance plans and healthcare costs projected to rise 9.5% in 2026, employers are increasingly pushing third-party administrators (TPAs) to deliver more flexible, cost-conscious network designs. PHCS Novera was built to meet that de
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors and host a presentation at the BofA Securities 2026 Global Health Care Conference in Las Vegas. The Company will webcast its presentation scheduled for 5:00 pm PT on Wednesday, May 13, 2026. To listen to the webcast, please visit https://investors.claritev.com/events-and-presentations/. For one-on-one meetings, please contact a representative at the host firm. About Claritev Claritev is a healthcare technology, data, and insights co
Q1 2026 Revenues of $244.7 million grew 5.8% compared to Q1 2025 Net Loss of $73.6 million Adjusted EBITDA of $146.9 million increased 3.4% compared to Q1 2025 (Adjusted EBITDA Margin of 60.0% versus 61.4% in Q1 2025) Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2026. "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence — confidence in our te
Recognition highlights Claritev's progress embedding AI into healthcare workflows to reduce cost, improve performance, and increase transparency Claritev, a healthcare technology, data, and insights company, today announced that Fernando Schwartz, Ph.D., Senior Vice President and Chief AI Officer, has been named to the DataIQ 100 North America list for 2026, recognizing leaders applying data and artificial intelligence to drive measurable impact across industries. The recognition reflects Claritev's progress in embedding AI into healthcare workflows to help reduce administrative complexity, improve financial performance, and support informed decision-making across the healthcare ecosyst
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its first quarter fiscal year 2026 financial results prior to market open on Thursday, May 7, 2026, and hold a conference call at 8:00 am Eastern Time. A live webcast of the conference call can be accessed through the Investor Relations section of the Company's website at investors.claritev.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. The earnings press release and supplemental slide deck
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced that members of its management team will meet with investors at the following investor events in March 2026: Mizuho Virtual Healthcare Technology Conference 2026 – Thursday, March 5, 2026 - 1x1 meetings hosted virtually Q&A Webcast Hosted by Nephron Research – Friday, March 6, 2026 at 11 a.m. ET. (Webcast details below) Barclays 28th Annual Global Healthcare Conference – Wednesday, March 11, 2025, at the Loews Miami Beach Hotel, Miami Beach, FL - 1x1 meetings To listen to the Q&A we
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, will host its 2026 Investor Day on Monday, March 16, 2026 at the New York Stock Exchange. The event will feature presentations by members of Claritev's management team discussing the company's long term growth strategy, vertical markets, product roadmap, and financial outlook, along with conversations with a number of clients and partners. The event and a live webcast will begin at 1:00 p.m. ET. Registration for the webcast can be found at https://www.claritev.com/investor-day-2026/. An archive of the webcast wi
Q4 2025 Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%) Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024) Full-year 2026 Guidance initiated: Revenue range of $980 million to $1 billion Free cash flow of $0 million to $10 million Capital expenditures of $160 million to $170 million Company Board of Directors approves $75 million, five-year share repurchase program Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insigh
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 23, 2026, and hold a conference call at 4:30 pm Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to the following
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's website at investors.claritev.com/events-and-presentations. For one-on-one meetings, please contact a representative at the host firm. About Claritev Claritev is a healthcare technology, data and insights company focused on im
Live Leadership Updates
Third annual report highlights the company's commitment to social and environmental stewardship Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the publication of its 2024 Corporate Responsibility Report. The 2024 report showcases the Company's strategic momentum in advancing its sustainability priorities during a pivotal year of transformation. The report emphasizes Claritev's continued focus on managing, tracking and disclosing its social and environmental performance, reinforcing its commitment to accountability and responsible
Strategic leadership and operational collaboration underscore Claritev's commitment to growth in the Middle East and international business development outside the US Claritev Corporation ("Claritev") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced it is deepening its investment in the Middle East North Africa ("MENA") region and the market outside the United States with the appointment of new regional leadership and a strategic operational collaboration. These moves reflect Claritev's continued focus on expanding its footprint and delivering localized, high-impact healthcare technology soluti
HOLLYWOOD, Fla., May 06, 2025 (GLOBE NEWSWIRE) -- Great Speech, a national leader in virtual speech therapy, is proud to announce a new agreement with Claritev, formerly known as MultiPlan (NYSE:CTEV), a technology and data insights company focused on making healthcare more affordable, transparent and fair for all. This network participation agreement marks a major step forward in expanding access to high-quality, convenient, and personalized speech therapy services for individuals and families nationwide. Great Speech's innovative teletherapy services will now be available to health plan members accessing Claritev's MultiPlan and PHCS Networks. The initiative aims to eliminate traditio
Board gains deep technology and innovation expertise to support Claritev's tech-driven growth strategy Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, yesterday announced the appointment of Jason Kap to its Board of Directors, effective immediately following his election at the Company's Annual Meeting of Shareholders on April 30, 2025. Kap brings more than two decades of leadership experience driving technology, pricing and product transformation strategies across the software and services industries, strengthening Claritev's focus on building a next-generati
Live finance-specific insights
Q1 2026 Revenues of $244.7 million grew 5.8% compared to Q1 2025 Net Loss of $73.6 million Adjusted EBITDA of $146.9 million increased 3.4% compared to Q1 2025 (Adjusted EBITDA Margin of 60.0% versus 61.4% in Q1 2025) Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2026. "Claritev kicked off 2026 the same way we closed 2025, outperforming on the top and bottom lines with focused execution in sales, operations and financials. We are operating with confidence — confidence in our te
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its first quarter fiscal year 2026 financial results prior to market open on Thursday, May 7, 2026, and hold a conference call at 8:00 am Eastern Time. A live webcast of the conference call can be accessed through the Investor Relations section of the Company's website at investors.claritev.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. The earnings press release and supplemental slide deck
Q4 2025 Revenues of $246.6 million, Net loss of $80.6 million, and Adjusted EBITDA of $151.3 million (Adjusted EBITDA Margin of 61.4%) Full-year 2025 Revenues of $965.4 million (increase of 3.7% compared to FY 2024), Net loss of $284.3 million, and Adjusted EBITDA of $602.6 million (increase of 4.5% compared to FY 2024) Full-year 2026 Guidance initiated: Revenue range of $980 million to $1 billion Free cash flow of $0 million to $10 million Capital expenditures of $160 million to $170 million Company Board of Directors approves $75 million, five-year share repurchase program Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insigh
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its fourth quarter and fiscal year 2025 financial results after market close on Monday, February 23, 2026, and hold a conference call at 4:30 pm Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to the following
– Q3 2025 Revenues of $246.0 million grew 6.7% compared to Q3 2024 – Net Loss of $69.8 million – Adjusted EBITDA of $155.1 million increased 9.5% compared to Q3 2024 (Adjusted EBITDA Margin of 63.1% versus 61.5% in Q3 2024) – Claritev raises full-year 2025 revenue and Adjusted EBITDA guidance Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the third quarter ended September 30, 2025. "We declared 2025 would be the Year of the Turn at Claritev. Our third quarter results and increased full year guidance demonstrate that w
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its third quarter 2025 financial results on Friday, November 7, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to the following link: https://www.net
Q2 2025 Revenues of $241.6 million, Net Loss of $62.6 million, and Adjusted EBITDA of $154.0 million (Adjusted EBITDA Margin of 63.8%) Full-year 2025 guidance updates to Revenue range (flat to +2% vs. 2024), Free Cash Flow range (usage of $20 million to generation of $20 million for year) and Capital Expenditures ($170 million to $180 million for year) Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the second quarter ended June 30, 2025. "Claritev is truly delivering in the year of The Turn. We returned to growth m
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its second quarter 2025 financial results on Wednesday, August 6, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadshow.com/eve
– Q1 2025 Revenues of $231.3 million, Net Loss of $71.3 million, and Adjusted EBITDA of $142.1 million (Adjusted EBITDA Margin of 61.4%) – Reaffirms full-year guidance Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today reported financial results for the first quarter ended March 31, 2025. "There is tremendous excitement at Claritev as we kick off 2025 - our ‘Year of The Turn.' We've already announced major milestones, and our teams are amplifying this positive momentum as we continue on our planned course for the year," said Travis Dalton, Chairman, CEO a
Claritev Corporation ("Claritev" or the "Company") (NYSE:CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its first quarter 2025 financial results on Thursday, May 8, 2025, and hold its conference call that morning at 8:00 am Eastern Time. To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time. To pre-register, go to: https://www.netroadshow.com/events/login?show=fda0